Can a second ADC tame breast cancer after the first fails?

NCT ID NCT06649331

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a different antibody-drug conjugate (ADC) to people with advanced breast cancer who have already tried an ADC can still shrink tumors or slow the disease. About 160 participants will receive one of several ADCs or a targeted pill. The goal is to see if rechallenging with a new ADC is safe and effective enough to control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
antibody-drug conjugates (SHR-A1811, SHR-A1921, SHR-A2009, SHR-A2102) and famitinib
What this could lead to
If successful, this could show that switching to a different ADC after one stops working is a viable strategy to control metastatic breast cancer.
What could go wrong
This is a small, early-phase trial with no control group, so results may not confirm effectiveness. ADCs can cause serious side effects like low blood counts or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Breast cancer institute of Fudan University Cancer Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.